Development asset linked to CureVac in public FDA and regional records.
pharma · metastatic squamous non-small cell lung cancer
CureVac
CureVac AG
CureVac drug portfolio — 2 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Tübingen, DE HQ
2000 Founded
639 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- Tübingen, DE
- Founded
- 2000
- Employees
- 639
- Programs
- 1
- Drugs
- 2
- Patents
- 0
CureVac pipeline
Portfolio lens on 2 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
CureVac drug portfolio — 2 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
pembrolizumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Programmed cell death protein 1.
- Target
- Programmed cell death protein 1
- Mechanism
- Programmed cell death protein 1 inhibitor